Abiopharma

🔍 Gundlach Andrew (Executive)

Company: WELLTOWER INC. (WELL)

Report Date: 2026-08-25

Detailed Transactions and Holdings:

• Acquired 2,500 shares of Common Stock at $239.47 per share (Direct)
  Date: 2026-08-25 | Code: P | equity_swap_involved: false | shares_owned_after: 22,500.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 2,500 shares of Common Stock at $239.47 per share (Direct)
  Date: 2026-08-25 | Code: P | equity_swap_involved: false | shares_owned_after: 25,000.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Acquired 2,500 shares of Common Stock at $242.06 per share (Direct)
  Date: 2026-08-26 | Code: P | equity_swap_involved: false | shares_owned_after: 27,500.00 | transaction_form_type: 4 | Footnotes: F4, F2
• Acquired 2,500 shares of Common Stock at $242.06 per share (Direct)
  Date: 2026-08-26 | Code: P | equity_swap_involved: false | shares_owned_after: 30,000.00 | transaction_form_type: 4 | Footnotes: F4, F3

Footnotes:

• F1: This transaction was executed in multiple trades at prices ranging from $239.27 to $239.50. The price reported above reflects the weighted average purchase price. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
• F2: The reporting person is the President and Chief Executive Officer of Bleichroeder LP, which serves as registered investment adviser to the trust, and is a beneficiary of the trust. The reporting person, on his own behalf and on behalf of Bleichroeder LP, disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that either the reporting person or Bleichroeder LP is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.
• F3: The reporting person is the President and Chief Executive Officer of Bleichroeder LP, which serves as registered investment adviser to the trust. The reporting person, on his own behalf and on behalf of Bleichroeder LP, disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that either the reporting person or Bleichroeder LP is the beneficial owner of the securities for purposes of Section 16 or for any other purposes.
• F4: This transaction was executed in multiple trades at prices ranging from $241.59 to $242.59. The price reported above reflects the weighted average purchase price. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.